--------------------- ------ ------ ---------- ------ ------- ----- ----- ----------
Profit Before Tax 246 87 182 % 38 553 % 183 (168) NA
--------------------- ------ ------ ---------- ------ ------- ----- ----- ----------
Tax 126 45 182 % 9 1,264 % 161 66 144 %
--------------------- ------ ------ ---------- ------ ------- ----- ----- ----------
Share of net profit
of associates 12 8 55 % 14 (14) % 59 54 9 %
--------------------- ------ ------ ---------- ------ ------- ----- ----- ----------
Net Profit after Tax
(before exceptional
item) 132 50 163 % 42 211 % 81 (180) NA
--------------------- ------ ------ ---------- ------ ------- ----- ----- ----------
Exceptional item* (31) 0 NA (32) NA (63) (7) NA
--------------------- ------ ------ ---------- ------ ------- ----- ----- ----------
Net Profit after Tax
(after exceptional
item) 101 50 102 % 10 902 % 18 (186) NA
--------------------- ------ ------ ---------- ------ ------- ----- ----- ----------
# FY23 EBITDA had one-time inventory margin impact of INR 68 Crore
--------------------------------------------------------------------------------------------
*Q3FY24 - Related to non-recurring charges towards product recall triggered by a
third-party supplier; Q4FY24 - Towards non-cash write down of investment and license rights
in relation to a certain third-party product no longer being commercialized
--------------------------------------------------------------------------------------------
Consolidated Balance Sheet
(In INR Crores)
As at
---------------------------------------------- ----------------------
Key Balance Sheet Items 31-Mar-24 31-Mar-23
---------------------------------------------- ---------- ----------
Total Equity 7,911 6,774
---------------------------------------------- ---------- ----------
Net Debt 3,932 4,781
---------------------------------------------- ---------- ----------
Total 11,843 11,555
---------------------------------------------- ---------- ----------
Net Fixed Assets 9,106 8,887
---------------------------------------------- ---------- ----------
Tangible Assets 4,250 3,589
---------------------------------------------- ---------- ----------
Intangible Assets including goodwill 3,740 3,880
---------------------------------------------- ---------- ----------
CWIP (including IAUD*) 1,116 1,419
---------------------------------------------- ---------- ----------
Net Working Capital 2,339 2,307
---------------------------------------------- ---------- ----------
Other Assets(#) 398 361
---------------------------------------------- ---------- ----------
Total Assets 11,843 11,555
---------------------------------------------- ---------- ----------
*IAUD -- Intangible Assets Under Development
# Other Assets include Investments and Deferred Tax Assets (Net)
Q4 and FY2024 Earnings Conference Call
Piramal Pharma Limited will be hosting a conference call for investors / analysts on 13(th) May 2024 from 9:30 AM to 10:15 AM (IST) to discuss its Q4 and FY2024 Results.
The dial-in details for the call are as under:
Event Location & Time Telephone Number
---------- ------------------------------------ --------------------------------------------------------
Conference India -- 09:30 AM IST +91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
call on
13(th)
May, 2024
---------- ------------------------------------ --------------------------------------------------------
1 800 120 1221 (Toll free number)
---------- ------------------------------------ --------------------------------------------------------
USA -- 12:00 AM Toll free number
(Eastern Time -- New York) 18667462133
------------------------------------ --------------------------------------------------------
UK -- 05:00 AM Toll free number
(London Time) 08081011573
------------------------------------ --------------------------------------------------------
Singapore -- 12:00 PM Toll free number
(Singapore Time) 8001012045
------------------------------------ --------------------------------------------------------
Hong Kong -- 12:00 PM Toll free number
(Hong Kong Time) 800964448
---------- ------------------------------------ --------------------------------------------------------
Express Please use this link for prior registration to reduce wait time at the time of joining the
Join with call --https://services.choruscall.in/DiamondPassRegistration/register?confirmationNu
Diamond mber=9765638&linkSecurityString=3bb8d8359c
Pass$(TM)$
---------- ----------------------------------------------------------------------------------------------
About Piramal Pharma Ltd:
Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions $(PPS)$, an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL's associate companies, AbbVie Therapeutics India Private Limited (formerly Allergan India Pvt Ltd), a joint venture between Allergan (now part of AbbVie) and PPL, has emerged as one of the market leaders in the ophthalmology therapy area. Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information, visit: https://www.piramalpharma.com/, Facebook, Twitter, LinkedIn
Logo: https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-results-for-q4-and-fy2024-302142534.html
SOURCE Piramal Pharma Ltd
/CONTACT: + 91 98210 20 110
(END) Dow Jones Newswires
May 10, 2024 13:45 ET (17:45 GMT)
Comments